Browse Category

NYSE:FOUR News 18 December 2025

Jared Isaacman NASA Today: Senate Confirms Billionaire Spaceflight Veteran as New NASA Administrator (Dec. 17, 2025)

Jared Isaacman NASA Today: Senate Confirms Billionaire Spaceflight Veteran as New NASA Administrator (Dec. 17, 2025)

WASHINGTON — Jared Isaacman, the billionaire entrepreneur and private astronaut best known for commanding the all-civilian Inspiration4 mission and SpaceX’s Polaris Dawn, was confirmed by the U.S. Senate on Wednesday, December 17, 2025, to lead NASA. The confirmation vote was 67–30, elevating Isaacman to the role of NASA administrator at a moment when America’s civil space program is juggling high-profile Moon and Mars ambitions, intense geopolitical competition with China, and renewed political scrutiny over budgets and contracting. Reuters+2AP News+2 Isaacman’s ascent is more than a headline about a famous space tourist taking a government job. It also signals how central commercial
18 December 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop